Abstract
Allogeneic haematopoietic stem cell transplantation is considered to be the only potentially curative treatment for CLL patients. However, this method is burdened with high morbidity and mortality, and long-term survival without evidence of disease can be expected in about one-third of patients.
In recent years, new drugs - signaling pathway inhibitors have been introduced that have significantly improved outcomes in CLL patients. Although they probably do not have a curative potential, these drugs can offer long-term disease control with very good quality of life.
Another new attractive treatment option is the application of T-lymphocytes with genetically engineered chimeric antigenic receptor (CAR-T cells). As in the case of allogeneic transplantation, this is the form of adoptive immunotherapy, but CAR-Ts treatment is targeted without the risk of complications associated with graft versus host disease.
In order to achieve optimal results, it will be necessary to find the accurate algorithm for combining all of the above mentioned treatment options.